Roy Massingham
Impact in
-
- Neuropeptides and Animal Physiology
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
- Physiology top 5%
- Nitric Oxide and Endothelin Effects
- Asthma and respiratory diseases
Papers in
-
- Neuroscience and Neuropharmacology Research 14
- Neuropeptides and Animal Physiology 11
-
- Receptor Mechanisms and Signaling 33
- Ion channel regulation and function 11
- Co-authors
- Salomón Z. Langer (11 shared papers)Pierre Chatelain (15 shared papers)Nicholas B. Shepperson (6 shared papers)Icilio Cavero (3 shared papers)D. Cambridge (4 shared papers)Michel R. Gillard (10 shared papers)Francoise M. Lefevre-Borg (2 shared papers)Michael J. Davey (4 shared papers)
In The Last Decade
Roy Massingham
83 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 123
- Cellular and Molecular Neuroscience 633
- Physiology 509
- Immunology and Allergy 108
- Biochemistry 127
- Cardiology and Cardiovascular Medicine 317
Countries citing papers authored by Roy Massingham
This map shows the geographic impact of Roy Massingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy Massingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy Massingham more than expected).
Fields of papers citing papers by Roy Massingham
This network shows the impact of papers produced by Roy Massingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy Massingham. The network helps show where Roy Massingham may publish in the future.
Co-authors
The 25 scholars most cited alongside Roy Massingham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2002 | 188 | |
| 2 | 1980 | 137 | |
| 3 | 1980 | 125 | |
| 4 | 2005 | 119 | |
| 5 | Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. | 1977 | 118 |
| 6 | 1977 | 103 | |
| 7 | 1982 | 100 | |
| 8 | 1981 | 85 | |
| 9 | 1998 | 71 | |
| 10 | 1982 | 66 | |
| 11 | 2003 | 59 | |
| 12 | 1975 | 59 | |
| 13 | 2003 | 59 | |
| 14 | 1973 | 55 | |
| 15 | 1992 | 55 | |
| 16 | 1985 | 51 | |
| 17 | 1981 | 50 | |
| 18 | 1998 | 45 | |
| 19 | 1983 | 45 | |
| 20 | 1981 | 43 |
About Roy Massingham
Roy Massingham is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology, Cardiology and Cardiovascular Medicine, Pharmacology and Physiology, having authored 88 papers that have together received 2.2k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (33 papers), Neuroscience and Neuropharmacology Research (14 papers), Ion channel regulation and function (11 papers), Neuropeptides and Animal Physiology (11 papers), Cardiac electrophysiology and arrhythmias (8 papers), Nitric Oxide and Endothelin Effects (7 papers), Mast cells and histamine (7 papers) and Eicosanoids and Hypertension Pharmacology (5 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (633 citations), Physiology (509 citations), Immunology and Allergy (108 citations), Biochemistry (127 citations) and Cardiology and Cardiovascular Medicine (317 citations). Roy Massingham has collaborated with scholars based in Belgium, France and Spain. Frequent co-authors include Salomón Z. Langer, Pierre Chatelain, Nicholas B. Shepperson, Icilio Cavero, D. Cambridge, Michel R. Gillard, Francoise M. Lefevre-Borg, Michael J. Davey, Nicole Moguilevsky and Margareta Hammarlund‐Udenaes. Their work appears in journals such as European Journal of Pharmacology, British Journal of Pharmacology, Inflammation Research, Journal of Pharmacology and Experimental Therapeutics and Life Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.